As patents expire on current antidepressants pharmaceutical companies are getting out of the market, according to an article in yesterday’s Vancouver Sun. In the latest example, AstraZeneca announced this week that it is writing off its $146.5 million investment in Targacept, which failed to perform better than placebo in trials. The worldwide market for antidepressants is itself depressed, according to the article, having fallen from $15 billion in 2003 to a predicted less than $6 billion in 2016.
Mad in America hosts blogs by a diverse group of writers. These posts are designed to serve as a public forum for a discussion—broadly speaking—of psychiatry and its treatments. The opinions expressed are the writers’ own.